Anticancer compounds
Novel compounds with specific structural features address the limitations of existing brain cancer treatments by penetrating the blood-brain barrier and effectively inhibiting tumor growth in glioblastoma.
Patent Information
- Application Number
- JP2022127080
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-02-01
- Filing Date
- 2022-08-09
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-02-01
AI Technical Summary
Current treatments for brain cancer, such as glioblastoma, are inadequate due to the inability of existing therapies to penetrate the blood-brain barrier and the heterogeneity of the disease, leading to limited efficacy and significant side effects.
Development of novel compounds of formula (I) that include specific alkyl, alkenyl, aryl, heteroaryl, and heterocycloalkyl groups, which can penetrate the blood-brain barrier and inhibit tubulin polymerization, potentially inducing apoptosis in cancer cells.
The compounds effectively cross the blood-brain barrier and exhibit high anti-proliferative activity against brain cancer, including glioblastoma, inducing apoptosis and inhibiting tumor growth.
Smart Images

Figure 0007590004000021 
Figure 0007590004000022 
Figure 0007590004000023
Abstract
Citation Information
Patent Citations
3(5)-amino-pyrazole derivatives, processes for their preparation and their use as antitumor agents
JP2003507329A
Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
JP2003507461A
tubulin inhibitor
JP2007513093A
Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
JP2007537300A
Phenylacetamides suitable as protein kinase inhibitors
JP2008538356A
